Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D; IMPACT and EMBRACE Collaborators; Eeles R. Mitra A, et al. Among authors: easton d. Br J Cancer. 2008 Jan 29;98(2):502-7. doi: 10.1038/sj.bjc.6604132. Epub 2008 Jan 8. Br J Cancer. 2008. PMID: 18182994 Free PMC article.
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
Kote-Jarai Z, Powles TJ, Mitchell G, Tidy A, Ashley S, Easton D, Assersohn L, Sodha N, Salter J, Gusterson B, Dowsett M, Eeles R. Kote-Jarai Z, et al. Among authors: easton d. Cancer Lett. 2007 Mar 18;247(2):259-65. doi: 10.1016/j.canlet.2006.05.003. Epub 2006 Jun 14. Cancer Lett. 2007. PMID: 16777318 Clinical Trial.
Overexpression of RAD51 occurs in aggressive prostatic cancer.
Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators; Eeles R, Foster CS. Mitra A, et al. Among authors: easton d. Histopathology. 2009 Dec;55(6):696-704. doi: 10.1111/j.1365-2559.2009.03448.x. Histopathology. 2009. PMID: 20002770 Free PMC article.
Mutation analysis of the MSMB gene in familial prostate cancer.
Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, Field H, Guy M, Al Olama AA, Morrison J, O'Brien L, Wilkinson R, Hall A, Sawyer E, Muir K, Hamdy F, Donovan J, Neal D, Easton D, Eeles R. Kote-Jarai Z, et al. Among authors: easton d. Br J Cancer. 2010 Jan 19;102(2):414-8. doi: 10.1038/sj.bjc.6605485. Epub 2009 Dec 8. Br J Cancer. 2010. PMID: 19997100 Free PMC article.
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D; UKGPCS Collaborators; Goldgar D, Eeles R. Kote-Jarai Z, et al. Among authors: easton d. Br J Cancer. 2011 Oct 11;105(8):1230-4. doi: 10.1038/bjc.2011.383. Epub 2011 Sep 27. Br J Cancer. 2011. PMID: 21952622 Free PMC article.
Germline BRCA1 mutations increase prostate cancer risk.
Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D; UKGPCS Collaborators; Goldgar D, Eeles R, Kote-Jarai Z. Leongamornlert D, et al. Among authors: easton d. Br J Cancer. 2012 May 8;106(10):1697-701. doi: 10.1038/bjc.2012.146. Br J Cancer. 2012. PMID: 22516946 Free PMC article.
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: easton d. Clin Cancer Res. 2006 Dec 1;12(23):7025-32. doi: 10.1158/1078-0432.CCR-06-1244. Clin Cancer Res. 2006. PMID: 17145824
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: easton d. Clin Cancer Res. 2006 Dec 1;12(23):7033-8. doi: 10.1158/1078-0432.CCR-06-1246. Clin Cancer Res. 2006. PMID: 17145825
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB, Fahey P, Chen X, McGuffog L; kConFab; Easton D, Peock S, Cook M; EMBRACE; Simard J; INHERIT; Rebbeck TR; MAGIC; Antoniou AC, Chenevix-Trench G. Spurdle AB, et al. Among authors: easton d. Breast Cancer Res Treat. 2010 Jul;122(1):281-5. doi: 10.1007/s10549-009-0601-0. Epub 2009 Nov 18. Breast Cancer Res Treat. 2010. PMID: 19921428 Free PMC article.
1,246 results